NASDAQ:ODT Odonate Therapeutics (ODT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ODT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.03▼$1.5552-Week Range N/AVolume87,682 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Odonate Therapeutics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Odonate Therapeutics Stock (NASDAQ:ODT)Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… ODT Stock News HeadlinesFebruary 6, 2024 | investing.comProQR Therapeutics NV (PRQR)March 29, 2023 | marketwatch.comOrally Disintegrating Tablet (ODT) Market 2023 | Future Exploration by 2030April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 19, 2023 | usatoday.comPfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packagingMarch 3, 2023 | benzinga.comFate Therapeutics Stock (NASDAQ:FATE), Analyst Ratings, Price Targets, PredictionsJanuary 31, 2023 | marketwatch.comOrally Disintegrating Tablet (ODT) Market Size 2023 with Big Company Segment, Cost-Effective Solutions Analysis Information 2029October 22, 2022 | seekingalpha.comODTC Odonate Therapeutics, Inc.September 14, 2022 | forbes.comOdonate TherapeuticsApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 10, 2021 | finance.yahoo.comODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODTNovember 22, 2021 | finance.yahoo.comOdonate Therapeutics Insider Sold Over $2.5M In Company StockOctober 27, 2021 | uk.finance.yahoo.comOdonate Therapeutics, Inc. (ODT)September 27, 2021 | nasdaq.comOne Odonate Therapeutics, Inc. (NASDAQ:ODT) insider upped their stake in the previous yearSeptember 8, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the FirmSeptember 6, 2021 | finance.yahoo.comA Odonate Therapeutics, Inc. (NASDAQ:ODT) insider increased their holdings last yearAugust 26, 2021 | barrons.comOdonate Therapeutics Inc.August 21, 2021 | benzinga.comODONATE INVESTIGATION INITIATED by Former...August 17, 2021 | finance.yahoo.comUpdate in Lawsuit for Investors in Odonate Therapeutics, Inc. (NASDAQ:ODT) Announced by Shareholders FoundationAugust 16, 2021 | finance.yahoo.comKaskela Law LLC Announces Stockholder Investigation of Odonate Therapeutics, Inc. - ODTAugust 13, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to InvestorsAugust 10, 2021 | benzinga.comNASDAQ: ODT Investor Notice: Update in Lawsuit against Odonate Therapeutics, Inc. announced by Shareholders FoundationAugust 7, 2021 | finance.yahoo.comThe Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of InvestorsJuly 27, 2021 | finance.yahoo.comOdonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021See More Headlines Receive ODT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Odonate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ODT CUSIPN/A CIK1717452 Webwww.odonate.com Phone(858) 731-8180FaxN/AEmployees145Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares28,530,000Free Float14,578,000Market CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesKevin C. TangChairman & Chief Executive OfficerRyan ColeSenior Vice President-OperationsMichael S. HearneChief Financial OfficerThomas WeiChief Scientific OfficerSteven PfeifferSenior Vice President-Technical OperationsKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors ODT Stock Analysis - Frequently Asked Questions How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics, Inc. (NASDAQ:ODT) posted its earnings results on Wednesday, November, 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.33. What other stocks do shareholders of Odonate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP). When did Odonate Therapeutics IPO? Odonate Therapeutics (ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager. This page (NASDAQ:ODT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Odonate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
